Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD6234 as Adjunct to Incretin-based Therapies in Obesity or Overweight (SELENE 3)
NCT07776509Phase 3Recruiting
- Sponsor
- AstraZeneca
- Start
- Aug 2026
- Primary completion
- Aug 2028
- Countries
- 11
01
Overview
A Phase 3 trial of lenbelintide in obesity, Overweight, sponsored by AstraZeneca. Started Aug 2026; status: recruiting.
02
Drugs
lenbelintide
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT07776509.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07776509.